Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexyme versus folic acid for clearance of high-risk HPV infection
IRCT20240424061554N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of folic acid in human papillomavirus infection (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: HPV clearance. Started May 2024; status: completed.
02
Drugs
folic acid
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on IRCT20240424061554N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240424061554N1.